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identiﬁed 64 vitamin D insufﬁcient subjects out of 150 primary OA knee
patients. These were randomized by random allocation table for inter-
vention. In cases a bolus dose of calciferol in 60,000 IU/day for 10 days
followed by 6,000 IU/month for six months was administered and in
controls a placebo in the same schedules and durations was given.
Primary outcome measures were clinical WOMAC scores (pain, stiffness
and physical function) and VAS for knee pain. Secondary outcome
measures were radiological features (joint space width, osteophyte
scores, subchondral sclerosis scores and tibio femoral alignment) and
KL grades. The serum levels of vitamin D were assessed by using
Enzyme Linked Immunosorbent Assay (ELISA) and calcium/phos-
phorus/alkaline phosphatase by UV end point method. Statistical
analysis was performed on an intension to treat basis.
Results: There was no signiﬁcant baseline difference of age, sex, anal-
gesic frequency, dietary vitamin D intake, serum levels of vitamin D,
calcium, phosphorus and alkaline phosphatase and in clinical and
radiological scores between the cases and controls. BMI (25.96 vs 25.65,
p¼0.75) and pain (10.94 vs 10.64, p¼0.66) was higher in the placebo
group although difference was not statistically signiﬁcant. There was no
signiﬁcant difference in radiological features and KL grades from
baseline and at 6 months in both the groups.
At six month, both the groups had an improvement inWOMAC and VAS
pain scores but vitamin D showed beneﬁt over placebo from baseline
(p<0.01); for WOMAC physical function vitamin D group showed
signiﬁcant improvement over placebo which remained same as their
baseline levels.
Conclusion: Although a long term study is being recommended to
establish radiological progression, if any, this short term randomized
placebo control trial yields a beneﬁcial effect of vitamin D in pain and
physical function outcomes in KOA. Vitamin D intake was beneﬁcial in
symptomatic improvement of KOA.42
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Purpose: Osteoarthritis (OA) is currently the single most expensive
condition among medicare patients in the US; however, even with this
large economic burden, there is no intervention to modify disease
progression. Amniotic membrane is an allograft material that has anti-
inﬂammatory and anti-ﬁbrotic properties along with low immunoge-
nicity. It has been used in multiple clinical applications in humans
ranging from corneal defects to tendon repair; however it is the efﬁ-
cacy of amniotic membrane as an OA therapy is unknown. Objective:
To quantitatively assess the efﬁcacy of injectable micronized human
AM as a disease modifying intervention in a surgically induced rat
model of OA. Hypothesis: Micronized AM delivered intra-articularly
into the rat stiﬂe joint would attenuate OA disease progression and
that EPIC-mCT could be used to quantitatively evaluate the efﬁcacy of
this intervention.
Methods: OA was induced surgically by medial meniscal transection
(MMT) performed in Lewis rats (300g-325g). 24 hours after surgery, 50
ml micronized human AM (80mg/ml; AmnioFix Injectable, MiMedx
Group, Inc.) or saline was injected intra-articularly into the stiﬂe joint
(n¼5 per group, per time point). Animals were euthanized at 72 hours
or 21 days. Samples from the 21 day time point were dissected and
prepared for EPIC-mCT imaging using a contrast agent of 30% Hexabrix
320 (Covidien, Hazelwood, MO). For the quantitative EPIC-mCT analysis,
localized analysis was performed on the region of OA development, the
medial 1/3 of the medial tibial plateau, as well as at sites of focal lesions
(Fig 2). Quantitative measures of cartilage attenuation (inversely
proportional to proteoglycan content), lesion volume, and incidence of
lesion (greater than 50% loss in cartilage thickness) and erosion (loss of
thickness less than 50%) were obtained. Samples were then decalciﬁed
and stained with Saf-O or H&E. Data are presented as mean  standard
error and evaluated using an ANOVAwith Tukey's test. Signiﬁcance was
set at p < 0.05.
Results: Amnion injected into healthy, non-MMT, stiﬂe joints produced
no change in cartilage attenuation (i.e. proteoglycan content) and nolesions. In both MMT animals and healthy control animals, amnion
particles were identiﬁed histologically in the synovium at 3 and 21 days
post-surgery (Fig 1). The particles appeared as variably sized linear
fragments of multi-layered eosinophilic ﬁbrillar material. In saline
treated MMT animals 21 days post-surgery lesions and incidence of
erosion were observed along with an increase in cartilage attenuation
(indicating decreased proteoglycan content). Treatment with injectable
amnion inhibited lesion formation and reduced incidence of erosion as
compared to saline treated animals (table 1). Similarly, amnion treat-
ment reduced cartilage attenuation, indicating increased proteoglycan
content, by 78% compared to saline treatment.
Conclusion: This study demonstrated the efﬁcacy of a novel injectable
formulation of AM to attenuate osteoarthritis development in a rat
MMT model. AM injection produced signiﬁcantly higher proteoglycan
levels, fewer sites of erosion, and complete prevention of lesion
formation. Amnion is an allograft product that is currently used for
many clinical indications suggesting that the injectable formulation
could quickly be translated into a clinical OA therapy.
Figure 1. Histology from MMT animals with saline or amnion treatment. H&E images
(10) showed the presence of amnion particles (black arrows) in the synovium 3 days
post-injection. Saf-O staining 21 days post-injection showed healthy cartilage and
more proteoglycans staining in MMT animals treated with amnion.
Figure 2. EPIC-mCT data 21 days after MMT surgery. Reconstructions of the tibial
articular cartilage with attenuation heat maps show lesions in the saline treated
animals and sites of erosion in the amnion treated animals. No lesions were observed
in the amnion treated animals. Saline treated MMT animals showed a loss of proteo-
glycans (higher attenuation) while amnion treated animals showed proteoglycan
levels comparable to the non-MMT control.
